NCT03323034: Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 6 Months to 21 Years (Child, Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: 
Exclusions: Patients over 21 years of age; Patients with prior exposure to pevonedistat

Comments are closed.

Up ↑